Effect of mirtazapine in reducing abnormal movements in patients with oromandibular dyskinesia.

Investigating the effect of mirtazapine in reducing abnormal movements in patients with oromandibular dyskinesia and comparing it with the control group immediately after treatment and 3 and 6 months later.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220623055257N2

Enrollment

Registered

2025-01-19

Start date

2025-01-20

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oromandibular dyskinesia. Idiopathic orofacial dystonia

Interventions

Intervention 1: Intervention group: They will be treated with mirtazapine tablets (Actoverco Company) at a dose of 7.5 mg orally every night, which will be increased to 30 mg every night within 3 week

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Suffering from oromandibular dyskinesia according to the diagnosis of a neurologist Individual consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy Opium addiction Taking SSRI drugs Bipolar disorder Sensitivity to Mirtazapine and Tetrabenazine

Design outcomes

Primary

Measure	Time frame
The score of Abnormal Involuntary Movement Scale (AIMS) questionnaire. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months later and 6 months later. Method of measurement: Abnormal Involuntary Movement Scale (AIMS) questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Imaneh Sabourifar

Esfahan University of Medical Sciences

sabourifarimaneh@gmail.com+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026